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Abstract 
THE INFLUENCE OF LIPID COMPOSITION ON THE BINDING OF LDL TO 
CHONDROITIN 6-SULPHATE 
By Wilma 0. Espiritu, M.S. 
Thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science in Biochemistry at Virginia Commonwealth University. 
Virginia Commonwealth University, 2005 
Major Director: Rik van Antwerpen, Ph.D. 
Assistant Professor, Department of Biochemistry 
The interaction between low-density lipoprotein (LDL) and glycosaminoglycans is 
a key factor in atherosclerosis. The present study examines the characteristics of LDL and 
its binding properties with the main glycosaminoglycan of the vascular wall, chondroitin 6- 
sulphate (C6S). The compositional characteristics that were studied for each LDL sample 
were phase transition temperature, phospholipid content, free cholesterol content, 
cholesteryl ester content, triglyceride content, and size. Correlations of these 
characteristics with LDL-C6S binding were analyzed using a turbidity assay. Our results 
showed that there is no correlation between LDL-C6S binding and phase transition 
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temperature, triglyceride content, or size. Strong correlations were present for LDL-C6S 
binding and phospholipid content (P < 0.0001, r2 = 0.4591), free cholesterol content (P < 
0.01, r2 = 0.2495), and cliolesteryl ester content (P < 0.005, r2 = 0.2952). When values for 
surface (phospholipids and free cholesterol) and core (cholesteryl esters and triglycerides) 
lipids were determined a positive correlation was also present with LDL-C6S binding (P < 
0.0005, r2 = 0.4172; P < 0.0005, r2 = 0.4282; respectively). These results indicate that 
large, lipid-rich LDL particles have a higher capacity to bind C6S than smaller, lipid poor 
LDL. Possible implications for the atherogenicity of LDL are discussed. 
CHAPTER 1 INTRODUCTION 
Atherosclerosis is a systemic disease that is characterized by the accumulation of 
lipid-rich plaques within the walls of large arteries. The major clinical outcomes of 
atherosclerosis are well known and include coronary heart disease, stroke, and peripheral 
vascular disease. It is the leading cause of mortality in men and women in modem 
nations.' Because of this fact, it is important to examine what the key factors are, how 
they become malicious, and what can be done to prevent or even eliminate the known 
outcomes. 
Starting from as early as the fetus,2 atherosclerotic lesions are formed and develop 
basically in three stages: endothelial dysfunction, fatty streak formation, and fibrous cap 
formation. Through the years three major atherosclerosis hypotheses have emerged to 
provide a starting point. They are the response-to-injury hypothesis, the oxidative 
modification hypothesis, and the response-to-retention hypothesis. 
1.1 Response-to-Injury Hypothesis 
Ross and Glomset proposed the response-to-injury hypothesis in the 1990s and 
pointed to endothelial dysfunction as a critical f a ~ t o r . ~  Endothelial injury can be caused by 
key risk factors which can be genetic and/or environmental, for example, elevated levels of 
cholesterol and triglyceride in the blood, high blood pressure, cigarette smoke, and 
v i r ~ s e s . ~  The hypothesis suggests that an endothelial injury initiates a cascade of 
responses that alter normal vascular homeostasis. Because of this endothelial dysfunction 
there is enhanced endothelial permeability and deposition of LDL particles in the intima. 
This also triggers leukocyte adhesion and transmigration across the endothelium. Soon 
after, inflammatory responses such as T-cell activation, platelet adherence and aggregation, 
and additional entry of leukocytes, smooth muscle cell migration and proliferation occur. 
After monocytes differentiate into macrophages they are able to take in LDL and form 
"foam cells". The final steps in this hypothesis involve continued foam cell formation, 
fibrous cap formation, and necrosis in the core of the l e ~ i o n . ~  
1.2 Oxidative Modification Hypothesis 
The next major atherosclerosis liypothesis, which has been widely researched and 
expanded upon, is the oxidative modification hypothesis. This hypothesis was first 
proposed in 1989 by Steinberg et al. and placed more emphasis on the LDL particle i t ~ e l f . ~  
The basis of this hypothesis stems from observations that LDL particles in their native 
state are not atherogenic and LDL particles that are modified chemically are atherogenic 
by being more susceptible to internalization by macrophages through a "scavenger 
receptor" pathway.7 This process begins when LDL crosses into the subendothelial space 
of a lesion prone area of the artery and becomes exposed to oxidation. Oxidation causes 
modification of the lysine groups on apo B-100; these modifications in turn cause the LDL 
particle to become more negatively charged and more susceptible to macropliage 
internalization. Oxidized LDL particles also stimulate monocyte recruitment into the 
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intimal space and prevent macrophages already in the intima from leaving. This increases 
the chances for more LDL to become oxidized and enter the scavenger receptor pathway. 
Since this is not a regulated pathway, uptake of cholesterol in oxidized LDL is continual 
and foam cell accumulation and foam cell necrosis  occur^.^ This necrosis results in 
endothelial dysfunction and i n j ~ r y . ~  
1.3 Response-to-Retention Hypothesis 
Finally, Williams and Tabas were the first to pioneer the response-to-retention 
hypothesis in 1995. They concluded that the key pathogenic event that is "both necessary 
and sufficient to provoke lesion initiation in a normal artery" is lipoprotein retention." 
Lipoprotein retention involves several key components which are proteoglycans in the 
extracellular matrix, lipolytic enzymes such as lipoprotein lipase and sphingoniyelinase, 
possibly other structural elements, and of course, atherogenic lipoproteins namely LDL. 
Williams and Tabas described a hypothetical pathway of the early stages of atherosclerosis 
starting with apo B containing lipoproteins entering the extracellular matrix by transcytosis 
and binding to arterial proteoglycans, which they call retentive molecules. This inward 
flow of lipoproteins causes LDL accumulation by proteoglycans and LDL aggregation by 
other arterial components like secretory sphingomyelinase. The accumulation and 
aggregation of lipoproteins further triggers a proinflammatory cascade that involves 
chemotaxis, adhesion molecule expression, and monocyte/leukocyte attachment and 
migration into the intima. Then the monocyte/leukocyte differentiates into a macrophage 
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which can take up modified LDL in the intima which can lead to foam cell formation and 
cause sn~ooth muscle cells to proliferate and migrate. (Figure 1) 
Ths pace m*a*. d w m r  Iho nbal agsr d Lpopown wtwd d r i u q ,  mnNton md eHur (m as a h p s  la, lh u;o~m*lm of 
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Figure 1 Early stages of atherogenesis. Schematic representation of the Response to 
Retention Hypothesis. Cm-remnant - chylomicron remnant, LPL - lipoprotein lipase, 
VLDL - very low-density lipoprotein, LDL - low-density lipoprotein. (Proctor et al.)' ' 
6 
These hypotheses of atherosclerosis are not mutually exclusive but rather 
emphasize different concepts as the necessary and sufficient events to support the 
developnient of atherosclerotic lesions.'* A time might come where all these hypotheses 
will ultimately fit together for a deeper understanding of the atherosclerotic process and it 
is not just one component that is the absolute critical. Until then, more questions need to 
be answered. Knowing this, there has been much research done based on the response to 
retention hypothesis, focusing on the interactions of proteoglycans and low density 
lipoproteins. In the sections to follow, the functions and structures of proteoglycans and 
glycosaminoglycans relating to atherosclerosis will be discussed along with a brief 
background of low density lipoproteins. 
1.4 Proteoglycans and Glycosaminoglycans 
Proteoglycans are complex molecules coniposed of a core protein and many 
covalently linked negatively charged glycosaminoglycan (GAG) chains. 13, 14 
Proteoglycans are generally assembled in the golgi apparatus of a mammalian cell; 
altliough, proteoglycans relevant to our discussion are produced in smooth muscle cells 
along with other components of the extracellular matrix like collagens and elastins. 
Proteoglycans are a major component found in the intima of large arteries. These 
molecules form a three-dimensional network that occupies 60% of the intima.'' There are 
many types of proteoglycans found in the body that hold different functions, but the 
proteoglycans that are most abundant in the vascular wall are veriscan and 
biglycaddecorin. Versican is a member of the aggrecan family and has a core protein of 
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-263 KD and 15 to 20 glycosaminoglycan (GAG) chains. It is made of about 70% 
chondroitin 6-sulphate, 20% chondroitin 4-sulphate (C4S), and 10% dermatan sulphate 
(DS). Biglycan and decorin are smaller proteoglycans with core proteins of 36-38 KD and 
2 to 3 GAG chains of DS or chondroitin sulphate (cs) '~  (Figure 2A). It has been reported 
by Wasty et. al. that the aforementioned CS and DS GAGs of lesion prone regions of 
human aortas have higher affinity for apo B lipoproteins than GAGs of non-lesion-prone 
aortic segments.17 Another GAG that has been associated with apo B binding is heparin.'' 
Chondroitin sulphate and dermatan sulphate are two of the six major 
glycosaminoglycan chains. Dermatan sulphate is a derivative of chondroitin sulphate 
(Figure 2B). Glycosaminoglycans are polysaccharides, mainly of repeating disaccharide 
units. One sugar of the disaccharide is either N-acetylglucosamine or N- 
acetylgalactosamine and the second is usually either glucuronic acid or iduronic acid.19 
Also, at least one of the sugars in the repeating unit has a negatively charged carboxylate 
or sulphate group. Chondroitin sulphate, keratan sulphate, heparin, heparan sulphate, 
dermatan sulphate, and hyaluronate are the major glycosaminoglycans.20 
Glycosaminoglycans are attached to serine residues of the protein core of the 
proteoglycans through a trisaccharide linker of galactose-galactose-xylose (Figure 3). 
Proteog lycans 
CS (30-50 Kd) 
Core protein , - 
(260 Kd) 
Core (40 Kd) P r o t e : y  
Glycosaminoglycans 
Chondroitin 6-sulphate Dermatan sulphate 
Figure 2 Proteoglycans and Glycosaminoglycans. (A) Versican and Biglycan/Decorin, 
examples of chondroitin sulphate proteoglycans. (B) Fisher diagrams of chondroitin 6- 
sulphate and derrnatan sulphate (derivatives of chondroitin sulphate). Adapted from 
Carnejo et. al. l 4  
glycosaminoglycan trisaccharide linker 
core protein fl 
I 








Figure 3 How Glycosaminoglycans Are Linked to the Protein Core of Proteoglycans. 
Adapted from M. W.  in^.^' 
10 
1.5 Lipoprotein Production and Cholesterol Metabolism 
Lipids can be produced both exogenously and endogenously.22 Exogenously, 
lipids, mainly triglyceride, come from the diet. These dietary lipids are absorbed by the 
small intestine, metabolized and secreted as chylomicrons. Chylomicrons are very large 
particles (1 80 - 500 nm and MW 400,000 KD) and can contain apolipoproteins E, C-11, C- 
111, A-I, A-11, and B-48. Once in the blood, lipoprotein lipase catabolizes the triglycerides 
in the chylomicrons to free fatty acids and glycerol. At the same time, there is a transfer of 
apo C-11, C-111, and E to HDL and a chylomicron remnant is formed. Chylomicron 
remnants contain one copy of apo B-48 and many copies of apo E. These remnants are 
then recognized by the liver through the LDL-receptor (apo B/E receptor) and the LDL- 
receptor related protein (LRP). Apo C-11, C-111, and E that are being carried by HDL get 
transferred back to chylomicrons still remaining in the blood and the cycle continues. 
Endogenously, lipids needed for the formation of lipoproteins are already present in 
the body. Synthesis and secretion both occur in the liver beginning with very low-density 
lipoproteins ( v L D L ) . ~ ~  VLDL is a large, triglyceride rich lipoprotein and contains 
apolipoproteins B 100, C, and E. As with the chylomicrons, lipoprotein lipase removes 
triglycerides along with apo C and phospholipids from VLDL to produce a VLDL remnant 
called intermediate density lipoproteins (IDL). IDL is converted to LDL by hepatic lipase. 
Hepatic lipase removes more triglycerides and the remaining apo E and a little more 
phospholipids creating a cholesteryl ester rich lipoprotein.23 Most LDL in the body is 
produced endogenously. 
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Endogenous production of cholesterol starts when acetyl-CoA from the citric acid 
cycle is converted to acetoacetyl-CoA by the enzyme thiolase and both the aforementioned 
substrates are condensed to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). HMG- 
CoA is then reduced to mevalonate by HMG-CoA reductase and NADPH. This is the first 
step in the HMG-CoA reductase pathway and the rate limiting step in cholesterol 
synthesis. (A class of drugs called statins, HMG-CoA reductase inhibitors, specifically 
targets this enzyme and irhibit cholesterol synthesis.) A long series of reactions produces 
hydrophobic molecules that are used for different but important tasks, such as, cell 
membrane maintenance, production of hormones, protein anchoring and ~ - ~ l ~ c o s ~ l a t i o n . ~ ~  
The transcription of the HMG-CoA reductase gene is enhanced by the sterol regulatory 
element binding protein (SREBP). The inactive form of SREBP is located in the ER. 
Once cholesterol levels fall SREBP is released from the ER by proteolysis and migrates to 
the nucleus where it binds to the sterol regulatory element (SRE) and transcription of 
HMG-CoA reductase begins. When cholesterol levels increase the SREBP is cleaved and 
degraded and transcription ceases. 
1.6 Low-Density Lipoproteins 
Low density lipoproteins have a density range between 1.01 9 and 1.063 glml and a 
particle size between 19 and 23 nm. Because of this, LDL is naturally heterogeneous. 
About 45% of the LDL particle's total weight is composed of a neutral lipid core 
containing cholesteryl esters and triglycerides. On the surface, the phospholipid 
monolayer comprises -20% of the particle's total weight, free unesterified cholesterol 
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-lo%, and apo B-100 the remaining -25% of the particle's total weight. Apo B-100 is the 
largest known protein containing 4,536 amino acids with three alternating regions of beta 
sheets and alpha helixes (figure 4). It has a molecular weight of 5 12,723. LDL is the 
major cholesterol carrying plasma lipoprotein. The native LDL particle is generally 
positively charged unless it becomes exposed to oxidation. Once oxidation occurs the 
particle slowly becomes more negatively charged. 
8 Phospholipids Cholesteryl 
Ester 




Figure 4 Low-Density Lipoprotein. (A) Schematic representation of an LDL molecule. 
(B) Schematic representation of the conformation of apo B 100. Segrest et al. (200 1) J. 
Lipid Res. 42: 1346- 1 36725 
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1.7 LDL's Function in the Body 
In the body, LDL functions as a major contributor in cholesterol metabolism. It is 
taken into the cell by process called receptor-mediated endocytosis. Apo B-100 on the 
surface of LDL binds to the LDL receptor, which is localized in a region that contains 
clathrin coated pits. The LDL and its receptor then become internalized by the clathrin 
forming a clathrin coated vesicle. Once completely in the cell the clathrin coat 
depolymerizes into triskelions and the vesicle becomes an early endosome. The early 
endosome fuses with a late endosome, also known as a sorting endosome, and the LDL 
separates from the LDL receptor because of the low pH of the environment. The LDL 
receptor is sent back to the plasma membrane where it is recycled and awaits another LDL 
particle. In the meantime, the late endosome that contains the LDL fuses with and 
becomes a lysosome. This is where the apo B-100 is degraded to amino acids and the 
cholesteryl esters are hydrolyzed into cholesterol and fatty acids. Since the metabolism of 
cholesterol is part of a negative feedback system, an abundance of cholesterol inhibits the 
synthesis of more cholesterol and the LDL receptor. 24,26 
Now that the key players in the atherosclerotic process have been discussed and 
identified, we can examine the binding properties of low-density lipoproteins with 
chondroitin 6-sulphate. 
1.8 Low-Density Lipoprotein - Glycosaminoglycan Interaction 
The present understanding is that the interaction between LDL and the GAG chains 
on proteoglycans occurs though ionic attraction between positively charged clusters amino 
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acids on apolipoprotein B-100 and the negatively charged sulphate groups on the GAG 
chains of proteoglycans.27 Chondroitin sulphate was chosen for our study because it is the 
most abundant glycosaminoglycan in the body and the predominant one in atherosclerotic 
lesions. (Chondroitin 6-sulphate was used specifically over chondroitin 4-sulphate because 
it is more sterically accessible to LDL complex formation.) 
1.9 Physical State of the LDL Core 
To assess the physical state of the LDL core, the phase transition temperature was 
determined by differential scanning calorimetry. Early studies by Deckelbaum et. al. 
characterized the different types of phase transitions of LDL, namely that of a reversible 
transition. This reversible transition in the LDL core takes place near body temperature 
and is associated with a liquid crystalline order-disorder phase change of cholesteryl 
esters.28 Later, our lab correlated the phase transition of the LDL core with changes in 
secondary structure of the apo B100. This indicated that the conformation of apo B100 
depends on the physical state of the LDL core and less on the composition of the core.29 
Since it has been shown in our lab that LDL samples from different individuals may have 
different phase transition temperatures the next logical progression in our research was to 
examine how these individual LDL samples bind to chondroitin 6-sulphate. 
1.10 Hypothesis 
In the present study, we examined the correlation between the physical state of the 
LDL core and the ability of the LDL particle to bind to chondroitin 6-sulphate. We 
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hypothesized that the physical state of the LDL core, through its influence on the 
conformation of apo B - ~ o o ~ ~ ,  influences the binding of LDL to C6S. 
The phase transition temperature of each LDL sample was determined by 
differential scanning calorimetry. LDL-C6S turbidity binding assays were performed for 
various LDL samples. Additionally, compositional analyses including assays for protein, 
total cholesterol, free cholesterol, triglyceride, and phospholipids were completed along 
with SDS PAGE to verify that apo B-100 was intact. 
Our results showed that the physical state of the LDL core does not have any affect 
on the LDL particle's ability to bind to chondroitin 6-sulphate. However, we found that 
certain lipids significantly correlated with binding, indicating that large, lipid-rich LDL 
particles have a higher capacity to bind C6S than smaller, lipid poor LDL. 
CHAPTER 2 MATERIALS AND METHODS 
2.1 Isolation of Lipoproteins 
Lipoproteins were isolated as described by Schumaker and ~ u ~ ~ i o n e . ~ ~  Fifty 
milliter blood samples were drawn from healthy, normolipidemic individuals after a 12 
hour fast. Samples were collected into five 10 ml Beckton Dickenson Vacutainer tubes 
(BD: Franklin Lakes, NJ) containing EDTA, then transferred into plastic centrifuge tubes 
and spun at 5,000 rpm for 20 minutes at 4OC using a Sorvall SS-34 rotor (Sorvall: 
Newtown, CT) in a Sorvall RC-5B refrigerated superspeed centrifuge (Dupont 
Instruments: Wilmington, DE). Once the blood cells and the plasma separated, the top 
clear plasma layer was collected and supplenlented with 5 mM disodium 
ethylenediaminetetraacetate (EDTA), 0.02% Sodium Azide (NaN3), 5 pglml gentamycin, 
0.2 Ulml aprotinin, and 50 pglml leupeptin (Sigma-Aldridge: St. Louis, MO). The 
densities of the plasma solution and deionized water were adjusted to a density range 
between 1 .019 to 1.2 1 (depending on which lipoprotein subclass is being separated) with a 
stock KBr solution and distributed equally into two Beckrnan ultracentrifuge tubes with the 
plasma in the bottom of the tube overlayed with the adjusted deionized water. A series of 
sequential ultracentrifugations were performed using a Beckman Ti70 rotor (Beckman 
Coulter: Fullerton, CA) to separate very low density lipoprotein (VLDL) and intermediate 
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density lipoprotein (IDL), low density lipoprotein (LDL), liigli density lipoprotein (HDL), 
and lipoprotein deficient plasma (LPDP).~' 
To remove the VLDLIIDL layer, whole plasma and an overlay solution was 
adjusted to a density of 1.019. The whole plasma was distributed between two Beckman 
ultracentrifuge tubes (Beckman Coulter: Fullerton, CA), overlayed, balanced and placed in 
the Beckman Ti70 rotor (Beckman Coulter: Fullerton, CA). The plasma was centrifuged 
in a Becknian L8M or L7-55 ultracentrifuge (Beckman Coulter: Fullerton, CA) for 19 to 
24 hours at 40,000 rpm and 20°C. After 24 hours, .the tubes were removed from the rotor 
and a separated VLDLIIDL top layer could be seen. Using a Pasteur pipette, the top 
VLDLIIDL layer was removed and properly discarded. The middle layer, which consisted 
of the overlay solution, was collected for density determination and also properly 
discarded. The bottom layer, which contains LDL and HDL was collected and used for 
further lipoprotein separation. The remaining plasma containing LDL and HDL was 
adjusted to a density of 1.063 and deionized water adjusted to the same density was used as 
an overlay. As before, the plasma was distributed between two Beckman ultracentrifuge 
tubes (Beckman Coulter: Fullerton, CA), overlayed, balanced, placed in the rotor and 
centrifuged for 19 to 24 hours at 40,000 rpm at 20°C. After 24 hours, the tubes were 
removed from the rotor and an apparent separation of LDL and HDL can be seen. A 
Pasteur pipette was used to collect the top layer of LDL. The LDL was desalted by an 
overnight dialysis in PBS containing 150 mM sodium chloride, 10 mM sodium phosphate, 
5 mM EDTA, and 0.02% azide aiid placed in a temperature controlled environment set to 
4°C. The middle overlay solution was used for density determination and then properly 
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discarded. The remaining plasma containing HDL was either separated by another 
centrifugation step for later use or properly discarded. 
After dialysis, LDL was recollected and transferred to an air tight plastic storage tube. The 
LDL sample was stored under argon at 4OC until further experimentation. 
2.2 Compositional Analysis 
Protein concentrations were determined by a modified Lowry procedure, using 
bovine serum albumin as a ~tandard.~ '  Total cholesterol, free cholesterol and 
phospholipids concentrations were determined by using enzymatic assay kits obtained 
from Wako Chemicals USA, Inc. (Richmond, VA). Cholesteryl ester concentrations were 
calculated by subtracting free cholesterol from total cholesterol and multiplying the value 
by 1 .68.32 ~ r i ~ l ~ c e r i d e  concentrations were determined by using an enzymatic assay kit 
obtained from ThermoTrace (Melbourne, Australia). All kit assays were performed using 
manufacturer's instruction. 
2.3 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS PAGE was performed using a procedure from ~ a e m m l i . ~ ~  Samples were 
prepared by adding 1 pl of LDL to 5 pl of deionized water and 10 pl of sample buffer. 
The sample buffer consisted of 20% glycerol (vlv), 25% Tris buffer (vlv) (1 M Tris, pH 
6.8), 2% mercaptoethanol (vlv), 10% SDS (wlv), and 1% Bromophenol Blue by weight. 
Each loading samples was prepared in a top perforated eppendorf and placed in a water 
bath and boiled for 5 minutes to denature the proteins. Meanwhile, a Tris-HC1 Ready gel 
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with a 4-1 5% linear gradient manufactured by Bio-Rad (Hercules, CA) was prepared. The 
gel was submerged in a Tris Buffer (25 mM Tris, 0.192 M glycine, 3.5 mM SDS in water, 
pH 8.3) and once loading samples were ready they were loaded into the gel. A prestained 
broad range standard (BioRad, control 947560) was used as a marker. After standard and 
samples were loaded, the gel underwent electrophoresis for about 30-45 minutes at 200 
volts until the samples ran to the bottom of the gel. Subsequently, the gel was removed 
from its cartridge and a coomassie stain (1% coomassie blue in 50% methanol, and 10% 
acetic acid) was applied for at least thirty minutes up to overnight. Subsequently, the gel 
was destained with a solution of 10% acetic acid, and 15% methanol.33 The destaining 
solution was applied for at least 8 hours. Stained gels were digitized using a flat bed 
scanner and the UMAX Magicscan program (Dallas, Texas). 
2.4 Differential Scanning Calorimetry (DSC) 
LDL samples were dialyzed in a bwffer containing 150 mM sodium chloride and 10 
mM sodium phosphate at pH 7.4 (PBS). Three milliliters of the dialysis bwffer was 
collected to serve as the reference for the baseline. LDL samples were diluted to a 
concentration of 0.7 mglml or greater. The reference and the sample were both degassed 
in a chamber that reached between 25 and 30 psi for 10 minutes. Using a Nano-I1 
Differential Scanning Calorimeter (Calorimetry Science Corporation: American Fork, UT), 
600 pl of LDL was loaded in a sample compartment and 600 pl of PBS was loaded in a 
reference compartment. A baseline was obtained by loading 600 pl of PBS in the sample 
compartment and 600 pl of PBS in the reference compartment. The accompanying 
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software was programmed to analyze 3 temperature-increasing (up-) scans and 3 
temperature-decreasing (down-) scans within the 5°C to 55OC temperature interval. Triple 
up- and down- scans were performed to demonstrate reversibility and reproducibility of the 
observed phase transitions. Data analysis was obtained by using CpConvert Software 
version 2.1.1 (Applied Thermodynamics: Hunt Valley, MD). 
2.5 Electrophoretic Mobility Shift Gels 
A 0.8% or 1.2% E-gel System precast agarose gel (Invitrogen Corporation: 
Carlsbad, CA) was used to determine the level of oxidation of the LDL samples in their 
native state. After preparing a LDL sample concentration of 7 pglml, 14 pglml Sudan 
Black was added and PBS at pH 8.6 was added to the reaction volume, totaling 20 pl in 
each well. The gel was pre-equilibrated without samples for two minutes. After loading 
the samples, the gel was run for 30-45 minutes at 60V. The gels were digitized using a flat 
bed scanner and the UMAX Magicscan program (Dallas, TX). 
2.6 Spectrophotometric Determination of Conjugated Dienes 
Conjugated dienes in an LDL sample were determined using a set protocol in 
spectrophotometer (Lamda 20 spectrophotometer Perkin Elmer: Nonvalk, C T ) . ~ ~  A 50 pg 
sample of LDL in 1 ml of PBS (without EDTA and NaN3) was prepared in a Fisherbralid* 
quartz cuvette (Fisher Scientific International: Pittsburg, PA). Another cuvette containing 
only PBS without EDTA and NaN3 served as the blank. The absorbance of the samples 
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was determined at 234 nm. LDL samples with absorbance in excess of 0.25 were 
considered oxidized and were not used for further analysis. 
2.7 LDL-C6S Turbidity Binding Assays 
Turbidity assays were carried out in a binding buffer that contained 2.5 mM Tris, 5 
mM CaC12, 1 mM magnesium chloride, and 7.5 mM sodium chloride, pH 6.0, essentially 
according to Hurt et. al.35 and Mourao et. ~ 1 . ~ ~ .  A stock solution of Chondroitin 6- 
sulphate (Sigma-Aldridge: St. Louis, MO) was made with a concentration of 0.1 mglml in 
the binding buffer. Chondroitin 6-sulphate was used at concentrations of 0.13, 0.25,0.50, 
0.75, 1.00, and 1.25 yglml, separately, in each assay. Twenty-five micrograms per milliter 
of an individual LDL sample was added to the binding buffer in a methacrylate cuvette 
(Fisher Scientific International: Pittsburg, PA) and used as a blank for the turbidity assay. 
Once the blank is recognized, the chondroitin 6-sulphate is added and the assay is 
incubated for 2 hours at either 37°C or 24°C. The total reaction volume was 1 ml. The 
turbidity of the solution was measured at 600 nrn using a Lamda 20 spectrophotometer 
(Perkin Elmer: Norwalk, CT). Turbidity assays were completed in triplicate for each 
individual LDL sample. 
2.8 Statistical Analysis 
Correlational analyses were performed using GraphPad Prism version 4.00 for 
Windows (GraphPad Software: San Diego, CA). Graphs with P-values of less than 0.05 
were significant. P-values were obtained from GraphPad Prism 4 software. 
2.9 Nuclear Magnetic Resonance Analysis - LipoScience, Inc. 
LDL size was determined by Nuclear Magnetic Resonance (NMR) Analysis, as 
described by Otvos et. al. 37 ,38  One milliter samples of whole plasma, which contains all 
the lipoproteins present - VLDL, IDL, LDL, and HDL - were collected in a sample 
container, frozen at -80°C, shipped to LipoScience, Inc. (Raleigh, NC) for NMR analysis. 
Typical data output sheets are shown in figures 5 and 6. Only LDL size data of the 
analyses were used for this study. 
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CHAPTER 3 RESULTS 
3.1 Physicochemical Characteristics of LDL 
A series of procedures were performed to characterize the composition of the 
various LDL samples. Assays for protein, total cholesterol, free cholesterol, 
phospholipids, and triglycerides showed that the LDL samples had normal amounts of each 
lipid. Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
confirmed that the protein component of LDL (apolipoprotein B- 100) was intact for each 
LDL sample. Measurement of conjugated dienes ensured that none of the LDL samples 
had oxidized. Differential Scanning Calorimetry (DSC) provided information on the 
physical state of the LDL core at a given temperature. 
3.1.1 Lipid Composition 
LDL from 28 healthy normolipidemic subjects were isolated by sequential 
centrifugation and their physical and chemical properties were analyzed. Assays for 
protein, total cholesterol, free cholesterol, triglyceride, and phospholipid showed that the 
LDL samples were compositionally consistent with other published results.12 Shown in 
figure 7A, the weight percentage of each lipid component in mean and standard deviation 
were as follows: 23.7 h 2.2 for protein, 9.8 h 0.7 for free cholesterol, 42.3 h 3.1 for 
cholesteryl ester, 4.6 h 1.9 for triglycerides, and 19.7 h 1 .O for phospholipids. To further 
confirm that the LDL samples only contained Apo B-100 and that this lipoprotein was 
intact, SDS PAGE was performed (figure 7B). If any contaminations were present like 
apo E (MW 34 kD), additional centrifugation would be completed to re-separate the 
different lipoproteins. 
A 
Compositional Analysis of NLDL 
0 NLDL 
EZZI C o n s e n s u s  
Protein FC CE TG Phos 
MW Markers Apoprotein 8-1 00 512,000 d 
i '-> 3 1 1 
Figure 7 Compositional Analysis LDL. (A) Protein - Apolioprotein B 100; FC - Free 
Cholesterol; CE - Cholesteryl Ester; TG - Triglyceride; Phos - Phospholipid. n=28. 
Error bars represent f SD. (B) SDS PAGE revealed that all LDL samples were intact 
forming a band above the first marker which is myosin at 21 0 kDa. Apo B-100 has a 
molecular weight of 5 12,723. 
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3.1.2 Level of Oxidation 
To provide the best environment for LDL to bind to C6S, one of the main factors is 
the particle charge and the level of oxidation of an LDL species. LDL is naturally a 
positively charged particle and C6S is a very negatively charged sugar, their fundamental 
attraction becomes obvious. Since LDL can be exposed to oxidation, the level of oxidation 
of the particle becomes important. Before performing C6S turbidity assays, each LDL 
sample has been supplemented with EDTA and NaN3 and assayed very soon after its 
isolation. To verify the absence of oxidation, the amount of conjugated dienes were 
detected at an absorbance of 234 nm. Only san~ples with detection values less than 0.25 
were considered not oxidized and used for further experimentation. (Data not shown). 
3.1.3 Phase Transition Temperature of LDL 
By determining the phase transition temperature of an LDL sample, it gives 
information about the physical state of the LDL core, whether it is liquid or liquid 
crystalline and possible conformation of apo B-100, at physiological temperature 37°C. 
Figure 8A represents a typical DSC output scan of an individual LDL sample. The area 
where the curve reaches its peak provides the phase transition temperature of this sample. 
In this example, the phase transition temperature is 27.5"C. The phase transition 
temperatures of 20 LDL samples from different individuals were determined. Figure 8B 
shows the range and variation of phase transition temperatures of a population of healthy 
individuals. The phase transition temperatures ranged from 22.0°C to 33.8"C. DSC was 
done in triplicate for each LDL sample, 3 up scans and 3 down scans. 
Ib 20 30 4b h 
A Temperature (OC) 
-" 
Healthy Subjects 
Figure 8 Phase Transition Temperatures. (A) Typical DSC scan. At least 0.5 mg/ml of 
apo B-100 protein dialyzed in PBS without EDTA and NaN3 are loaded into an N-DCS-I1 
Differential Scanning Calorimeter. PBS without EDTA and NaN3 are loaded in the 
reference cell. The temperature range was set for 5°C to 55OC. Samples were run in 
triplicate - 3 up scans and 3 down scans. (B) Phase transition temperatures taken from 20 
LDL samples, determined by differential scanning calorimetry. 
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3.2 LDL:C6S Complex Formation 
Turbidity assays were performed to determine binding capacities of 28 different 
individual LDL samples to chondroitin 6-sulphate. For each LDL sample, turbidity assays 
were conlpleted in triplicate with the average value used for data analysis. Preliminary 
studies were done to determine equilibration time and saturation. 
Figure 9A is a typical time drive experiment. This time drive experiment measures 
how turbid the reaction volume becomes over time. The turbidity is caused by the cross 
linking of the C6S with the LDL in the presence of the binding buffer. 25 yglml of apo B 
protein from each LDL sample was incubated with varying concentrations of chondroitin 
6-sulphate, between 0.13yglml- 1.25 yglml in binding buffer. At each of the different 
C6S concentrations the time at which the reaction had reached equilibrium appeared to do 
so at about two hours. The lowest absorbance reading was observed when the lowest 
amount of C6S, 0.13 pglml, was used in the turbidity assay. Tlie absorbance gradually 
increased when 0.25, 0.50, and 0.75 yglml of C6S was added (in separate assays) and 
peaked and leveled off with 1 .OO and 1.25 yglnil of C6S. After the 2 hour equilibration 
period, when all binding sites are occupied, saturation occurs. All experiments were 
performed in a temperature controlled environment at 37OC. Figure 9B represents the 
maximum absorbance values of .the increasing amounts of C6S. It also shows how two 
different individuals can have different levels of binding to C6S. In figure 9C, each dot 
represents an individual LDL sample taken from different healthy individuals. Similar to 
figure 8B (Phase Transition Temperature versus Healthy Subjects), this shows that in a 
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population of healthy individuals the level of LDL:C6S binding can vary over a 5-fold 
range. 




Figure 9 Chondroitin 6-Suphate Turbidity Assays. (A) Typical Time Drive Experiment 
with Increasing C6S concentration. 25 pglml of an LDL sample was incubated with 
varying concentrations of chondroitin 6-sulphate, between 0.13 pg/ml - 1.25 pg/ml in a 
binding buffer of 5mM CaC12, 2.5mM Tris, 1 .OmM MgC12, and 7.5mM NaCl. Incubations 
were completed to equilibration after 2 hours at 37OC. (B) Maximal Binding Capacity of 
2 Different Individuals. Experiments were carried as previously stated. Maximal binding 
values were plotted against increasing C6S concentrations. (C) 28 LDL samples 
underwent C6S turbidity assays. Each assay was preformed in triplicate with 25 pglml 
LDL, 1.25 pglml C6S, and binding buffer for 2 hours at 37OC. 
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To measure the amount of apo B-100 that aggregated with C6S, protein assays 
were completed for a sample that exhibited a higher absorbance value and a sample that 
had a much lower absorbance value. These same samples were incubated in one set of 
experiments with varying LDL concentrations and constant C6S concentrations and a 
second set wit11 varying C6S concentrations with constant LDL concentrations. Figure 10 
shows the results of this experiment. When binding experiments were completed for each 
of these conditions, the reaction mixtures were centrifuged and the pellets were isolated 
and resuspended for apo B protein determination. It is concluded from this set of data that 
a "high" binding LDL sample was binding more LDL particles to C6S and that the "low" 
binding LDL sample was binding fewer LDL particles. A "high" binder is an LDL sample 
with absorbance detection (E600 nm) of 0.4500 or more. A "low" binder is an LDL 
sample with absorbance detection (E600 nm) of 0.2500 or less. Similar results were 
apparent in both experimental conditions. 
high 
low 
Figure 10 Particle Number versus Aggregation Size. C6S Turbidity Assay Using Varying 
C6S Concentrations. C6S assays were performed with constant LDL concentration of 25 
pglml and varying concentrations of C6S ranging from 0.13 pg/ml to 1.25 pglml. All 
assays were completed after 2 hours at 37OC. After 2 hours the reaction mixtures were 
centrifuged and pellets were formed. Protein concentrations of the pellets were 
determined. 
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3.3 Phase Transition Temperature of the LDL Core and C6S Binding 
The phase transition temperatures of 20 different LDL samples were determined by 
differential scanning calorimetry. The phase transition temperature provides information 
on the fluidity of the LDL core at a given temperature. These same LDL samples 
underwent C6S turbidity assays at 37OC and 24OC. Our original hypothesis suggested that 
the physical state of the LDL core, being liquid or liquid crystalline, affects the binding of 
the LDL particle to chondroitin 6-sulphate. 
The level of aggregation of LDL and C6S glycosaminoglycan chains was measured 
at an absorbance wavelength of 600 nm. As previously shown, in an isolated population of 
healthy individuals, they exhibit a range of phase trai~sitioi~ temperatures and a range of 
LDL:C6S aggregation. As shown in figure 1 IA, turbidity (absorbance at 600 nm) and 
phase transition temperature did not correlate (P < 0.05). Figure 11B pairs each sample at 
37°C (when the core is in the liquid state) and 24°C (when the core is in the liquid- 
crystalline state). When both pieces of information are plotted together, the results 
disproved our initial assumption; the physical state of the LDL core does not correlate with 
the level of binding of LDL to C6S. 
Figure 1 1 Maximal Binding of LDL to C6S. (A) versus Phase Transition Temperature. 
C6S turbidity assays were performed as mentioned. Assays used 25 pglml of LDL and 
1.25 pglml of C6S for 2 hours and separately at 24OC and 37°C. Absorbance was 
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3.4 LDL Lipid Composition and C6S Binding 
Since no correlation was found between the fluidity of the LDL core and the 
binding of the LDL particle to C6S. Other factors contributing to C6S binding have to be 
explored. The specific factors that were chosen to provide additional information on C6S 
binding were the individual lipid conlpositions of each LDL preparations. Leading up to 
our next hypothesis that the lipid con~position of the LDL particle contributes to the 
binding of the LDL particle to chondroitin 6-sulphate. 
As previously mentioned, the fluidity of the LDL core determined by the phase 
transition temperature is caused by the arrangement of cholesteryl esters and triglycerides. 
To determine if these components had any direct relationship to LDL binding to C6S, a 
series of compositional correlations were proposed. Figure 12 shows the individual lipid 
components (figures 12A, 12B, 12D, and 12E) as well as the combination of surface lipids 
and core lipids (figure 12C and 12F, respectively). Separately, the amounts of 
phospholipids, free cholesterol, and cholesteryl esters showed significant correlations with 
the level of binding of LDL to C6S. All of these graphs show a positive correlation for 
greater binding as phospholipids (P < 0.0001, r2 = 0.4591), free cholesterol (P < 0.01, r2 = 
0.2495), or cholesteryl esters (P < 0.005, r2 = 0.2952) increase. Triglycerides showed no 
significant correlation with binding (P > 0.5, r2 = 0.01709). When phospholipids were 
combined with free cholesterol, as they are naturally as surface lipids, the correlation 
remained positive and significant (P < 0.0005, r2 = 0.4172). Also when the cholesteryl 
esters and triglycerides were combined, as they naturally are as core lipids, their 
correlation became better than cholesteryl esters alone. The correlation of the core lipids 
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and C6S binding became positive and significant (P < 0.0005, r2 = 0.4282) even though 
triglycerides only showed no correlation with binding. 
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Figure 12 Maximal Binding of LDL to C6S versus Lipid Composition. Each open circle 
represents an individual LDL sample. Assays for protein, phospholipid, free cholesterol, 
total cholesterol, and triglycerides were performed. Values were calculated as a weight to 
weight ratio (wlw), lipid per protein. Cholesteryl esters were calculated by subtracting free 
cholesterol from total cholesterol and multiplying that value by 1 .68.32 Surface lipids were 
calculated as phospholipids and free cholesterol per protein. Core lipids were calculated as 
cholesteryl esters and triglycerides per protein. 
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Next, we used the same compositional data as previously mentioned and plotted it 
against 20 LDL samples that had known particle sizes to observe any significant 
correlations. Figure 13 illustrates the results. Again, phospholipids exhibited a stronger 
correlation with particle size (P < 0.05, r2 = 0.2905, figure 13A) than any of the other 
individual lipid components. Free cholesterol and cholesteryl esters were also both 
significantly correlated with particle size (P < 0.05, r2 = 0.2028, figure 13B; P < 0.05, r2 = 
0.2772, figure 13D; respectively) and triglycerides, as before in C6S binding (figure 12D), 
did not correlated with particle size (P = 0.5, r2 = 0.02576, figure 13D). When 
compositional data for phospholipids and free cholesterol were combined, as they are as 
surface lipids, the correlation improved (P < 0.01, r2 = 0.3 15 1, figure 13C). Also, when 
cholesteryl esters were combined with triglycerides, as they are as core lipids, the 
correlation became significant (P < 0.05, r2 = 0.2019). 
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Figure 13 Lipid Composition versus Particle Size. The same data from compositional 
assays were used as before. Particle size was provided by Liposcience, Inc. n = 20. 
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Finally combining the total lipid content (phospholipids, free cholesterol, 
cholesteryl esters, and triglycerides divided by protein content) and comparing that with 
the maximal binding gives a strong correlation (figure 14A, P < 0.0001, r2 = 0.4538). All 
of the graphs presented in figure 12 and figure 14 (except figure 14C) provide a strong 
indication that a larger LDL particle binds better to C6S than a smaller particle. To 
confirm this assumption, two more correlations were addressed - total lipid content versus 
LDL particle size and maximal binding of LDL to C6S versus LDL particle size. First, the 
value for total lipid content was used as above and plotted against LDL size (nm) derived 
from NMR analysis. Figure 14B demonstrates that more total lipids per particle does 
positively correlate with a larger particle size (P < 0.05, r2 = 0.2619). However, when the 
level of binding of LDL to C6S was compared with LDL particle size, no significant 
correlation was found (figure 14C). 
2.01 1 I I I 20 21 22 23 
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c P 0.01186 P value 0.6477 
0.61 I 
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Figure 14 Maximal C6S Binding, Lipid Content, and LDL. Each open circle represents an 
individual LDL sample. Each assay was completed with 25 pglml of LDL and 1.25 pg/ml 
of C6S. (A) Maximal C6S Binding versus Lipid Content per Protein. n=28. (B) Total 
Lipid Content per Protein versus Particle Size. n=20. (C) Maximal C6S Binding versus 
Particle Size. n=20. 
CHAPTER 4 DISCUSSION 
In the present study, we investigated the interactions of a variety of LDL samples 
and their binding properties to purified chondroitin 6-sulphate. The physical state of the 
LDL core was of particular interest because of its relationship with the conformation of 
apo ~ 1 0 0 . ~ '  The fluidity of the LDL core was determined by its phase transition 
temperature. Our results illustrated that the physical state of the core does not indicate a 
strong correlation to the level of binding of the LDL particle to chondroitin 6-sulphate. 
However, results pertaining to our second hypothesis demonstrate that the LDL 
composition is directly related to the binding of the LDL particle to chondroitin 6-sulphate. 
The amount of phospholipids, specifically, shows the best correlation to the LDL particle 
binding to C6S. 
4.1 Particle Size: Small versus Large 
Not much is mentioned in the literature about LDL lipid composition and its 
relationship with the interaction between LDL and proteoglycans or glycosaminoglycans. 
Our results show that the strongest correlation between LDL and C6S binding is with LDL 
phospholipid content (P < 0.0001, r2 = 0.4591) as presented in figure 12A. Phospholipids 
are found on the LDL particle as surface monolayer lipids. Also, when the amount of 
phospliolipids per LDL particle of each individual sample was analyzed with particle size, 
it gave the strongest correlation above any of the other lipid components (P < 0.05, r2 = 
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0.2905 figure 13A). Studies have associated both extremes of subclasses, the larger 
buoyant39, 40 and smaller denser41 LDL subfractions interacting better with arterial 
proteoglycans. 
In a recent review Lada and Rudel, explored the relationship of LDL size, small 
dense LDL versus large buoyant LDL, and its level of a t h e r ~ ~ e n i c i t ~ . ~ ~  Small dense LDL 
has received much notoriety as being the more atherogenic LDL subclass. 43,44,45,46 
Possible mechanisms linking small dense LDL as more atherogenic includes it's altered 
apo B conformation which causes a lowered affinity for the LDL-receptor resulting in 
43,44 longer residence time in the circulation, increased susceptibility to ox ida t i~n?~  
increased interaction with the scavenger receptor,45 and it's ability to easily enter the 
arterial wall because of its smaller LDL particle size.46 Another feature of small dense 
LDL is that it contains little or no sialic acid.48 Sialic acid may contribute to the size, 
and charge of the LDL particle. 50,51 Another major factor that places small 
dense LDL under the spotlight is its role in the metabolic syndrome. The metabolic 
syndrome is typically associated with elevated triglyceride levels, low HDL levels and a 
predominance of small dense LDL. Because of this association, research has found that 
the correlation between small dense LDL as risk factor for CHD also finds high levels of 
triglycerides and low levels of H D L . ~ ~  AS a result, small dense LDL has yet to become an 
independent risk factor for cardiovascular diseases. 
On the other hand, there has been growing evidence that large LDL may be the 
more atherogenic subfraction. Campos and co-workers 393 40 have found that in a 
normolipidemic population with coronary artery disease, large LDL was associated with 
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increased VLDL and reduced HDL2 cholesterol levels. Interestingly, after they made 
adjustments for low HDL cholesterol, high VLDL cholesterol, age, and BMI, large LDL 
was still an independent risk factor for CAD. 39,40 It has been show11 that large LDL also 
has low affinity for the LDL receptor, as does small dense LDL, resulting in a longer 
residence time in the blood.44 Further studies in nonhuman primates also indicated that 
large LDL particles contain high amounts of cholesteryl esters in the liquid crystalline state 
at body temperature, they deliver more cholesteryl ester per particle to cells in the arterial 
wall, and are associated with increased plaque formation. 53,54 
4.2 Arterial Proteoglycans versus Purified Glycosaminoglycans 
Numerous studies have been done on the binding of arterial proteoglycans to LDL 
but very few on purified glycosaminoglycans. The most studied proteoglycans are ones 
that consist primarily of chondroitin sulphate. As described in the introduction, 
proteoglycans consist of various numbers and combinations of glycosaminoglycans 
attached to a core protein. For example, Anber et used arterial proteoglycan pools, 
separated by density, containing a core protein and various amounts of chondroitin 
sulphate, dermatan sulphate, keratan sulphate, hyaluronic acid. They used a standard 
solution of arterial proteoglycans that contained 25 pglml of chondroitin sulphate in a 
binding buffer.44 In our experiments purified chondroitin 6-suphate glycosarninoglycan 
was used. It has been suggested that positively charged amino acid clusters on apo B 100 
are attracted to the highly negatively charged glycosaminoglycans from proteoglycans. 27 
Steele et al. have confirmed that LDL particles do not bind to the core protein.55 ~ur ther  
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studies in proteoglycans-LDL binding have shown that the extent of binding is dependent 
upon the amount of LDL, the concentration of proteoglycans,56 the degree of 
glycosaminoglycan ~ulfation,'~ glycosaminoglycan chain length, and possibly the sites of 
~ u l f a t i o n . ~ ~  Ballinger et al. have suggested that chondroitin 6-sulphate is more sterically 
accessible to a positively charged apo Bl 00 than chondroitin 4-sulphate which is a more 
rigid molecule.56 Differences may also arise in the origin of proteoglycans. For example, 
proteoglycans produced by smooth muscle cells (in the presence of transforming growth 
factor beta 1 58) have different binding properties than proteoglycans secreted by 
m a c r ~ ~ h a ~ e s . ~ ~  As described above, multiple factors affect the binding properties of 
proteoglycans. In our experiments, we examined only one glycosaminoglycan, the most 
abundant in the arterial wall, chondroitin 6-sulphate. In using only chondroitin 6-sulpliate 
at constant concentrations, we were able to attribute any changes in binding to the LDL 
particles of the different individual samples. 
Content determines size, so it would be reasonable to assume that, since LDL lipid 
content is related to LDL-C6S binding then LDL size is related to C6S binding. But, as 
indicated by our results, LDL size does not appear to correlate with C6S binding. How 
could that be? Compositional results coincided with other previously published data; 
however, size data that was used was not the most accurate determination for this study. 
Because LDL is naturally heterogeneous, the size that was determined by LipoScience was 
that of an average population size for an individual sample. Therefore the size value that is 
given is a single value representation of all the different subclass sizes within an individual 
sample. 
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Recommended future experimentation could include lipid composition 
determination after turbidity assay, more importantly, phospholipid concentration. 
Determining the lipid composition of the LDL particles that have attached to the 
chondroitin 6-sulfate can provide information about the subclass particularly involved. 
Another alternative experimental step could be to perform separation of LDL subclasses by 
density gradient ultracentrifugation. This can possibly indicate which subclasses bind 
more and which ones bind the least. 
At this point, the best indicator for LDL-C6S binding is phospholipid content. 
Since size data was determined as an average size in a population of LDL particles of an 
individual LDL sample, the LDL samples may contain varying percentages of LDL 
subclasses. But, since size had not correlated with chondroitin 6-sulphate binding and 
correlated instead with lipid content, then that provides more evidence that size is not a 
good indicator for atherogenicity. 
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